Herein it revealed that in contrast to this ErbB2-Herceptin line, the YS110 treatment abundantly induces nuclear localization of CD26 and in consequentially suppresses POLR2A expression, leading to inhibition of tumor cell growth. Here, ERBB2 is linked to neoplasm.